Moulis Guillaume, Palmaro Aurore, Sailler Laurent, Lapeyre-Mestre Maryse
UMR 1027, INSERM, Université de Toulouse III, Faculté de Médecine, Toulouse, France.
Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
PLoS One. 2015 Nov 11;10(11):e0142217. doi: 10.1371/journal.pone.0142217. eCollection 2015.
Corticosteroid (CS)-related infection risk in immune thrombocytopenia (ITP) is unknown. The aim of this study was to assess the adjusted CS risk function of severe infection in persistent or chronic primary ITP adults. We designed a nested case-control study in the FAITH cohort. This cohort is built through the French national health insurance database named SNIIRAM and includes all treated incident persistent or chronic primary ITP adults in France (ENCePP n°4574). Patients who entered the FAITH cohort between 2009 and 2012 were eligible (n = 1805). Cases were patients with infection as primary diagnosis code during hospitalization. Index date was the date of first hospitalization for infection. A 2:1 matching was performed on age and entry date in the cohort. Various CS exposure time-windows were defined: current user, exposure during the 1/3/6 months preceding index date and from the entry date. CS doses were converted in prednisone equivalent (PEQ). The cumulative CS doses were averaged in each time-window to obtain daily PEQ dosages. Each CS exposure definition was assessed using multivariate conditional regression models. During the study period, 161 cases (9 opportunistic) occurred. The model with the best goodness of fit was CS exposure during the month before the index date (OR: 2.48, 95% CI: 1.61-3.83). The dose-effect relation showed that the risk existed from averaged daily doses ≥5 mg PEQ (vs. <5 mg: 2.09, 95% CI: 1.17-3.71). The risk of infection was mainly supported by current or recent exposure to CS, even with low doses.
免疫性血小板减少症(ITP)中与皮质类固醇(CS)相关的感染风险尚不清楚。本研究的目的是评估持续性或慢性原发性ITP成年患者严重感染的调整后CS风险函数。我们在FAITH队列中设计了一项巢式病例对照研究。该队列通过名为SNIIRAM的法国国家健康保险数据库建立,包括法国所有接受治疗的新发持续性或慢性原发性ITP成年患者(ENCePP编号4574)。2009年至2012年进入FAITH队列的患者符合条件(n = 1805)。病例为住院期间以感染作为主要诊断代码的患者。索引日期为首次因感染住院的日期。根据年龄和队列入组日期进行2:1匹配。定义了各种CS暴露时间窗:当前使用者、索引日期前1/3/6个月以及从入组日期开始的暴露。CS剂量转换为泼尼松等效剂量(PEQ)。在每个时间窗内对累积CS剂量进行平均以获得每日PEQ剂量。使用多变量条件回归模型评估每个CS暴露定义。在研究期间,发生了161例病例(9例为机会性感染)。拟合优度最佳的模型是索引日期前一个月的CS暴露(OR:2.48,95%CI:1.61 - 3.83)。剂量 - 效应关系表明,平均每日剂量≥5 mg PEQ时存在风险(与<5 mg相比:2.09,95%CI:1.17 - 3.71)。感染风险主要由当前或近期接触CS支持,即使是低剂量。